|
Company Name |
Veritas In Silico Inc. |
|
|
Title and Name of Representative |
Representative Director and CEO |
Shingo NAKAMURA |
|
Head Office |
1-11-1 Nishi-gotanda, Shinagawa-ku, Tokyo |
|
|
Established |
November 17, 2016 |
|
|
Capital |
10,000,000 yen (as of April 1, 2026) |
|
|
Directors and Executive Officers |
Representative Director and CEO |
Shingo NAKAMURA |
|
Director, General Manager of Administration |
Hiroaki HAGIWARA |
|
|
Director, General Manager of Business Development |
Isao KODA |
|
|
Director |
Kinichiro KOMINAMI |
|
|
Director |
Tomoko SATO |
|
|
Audit & Supervisory Board Member |
Eiji HAMANO |
|
|
Audit & Supervisory Board Member |
Minoru HIROOKA |
|
|
Audit & Supervisory Board Member |
Minako WAKABAYASHI |
|
|
Number of Employees |
23 (as of June 1, 2026) |
|
|
Business |
Creating mRNA-targeted small molecule drugs with pharmaceutical companies as partner, utilizing our proprietary drug discovery platform, aibVIS, as well as developing nucleic acid medicine as its pipelines. |
|